Alzheimer |
Intraparenchymal |
Aβ |
Mice |
AAV1 |
[12] |
Intraparenchymal |
APOE2 |
Mice |
AAV9 and AArh10 |
[13] |
Intraparenchymal |
shIRS1 (IRS1: neuroprotective role) |
Rats |
AAV2/DJ8 |
[14] |
Intraparenchymal |
CCL2 (diffuse amyloid plaques) |
Mice |
AAV1/2 |
[15] |
Intraparenchymal |
ECE (protease involved in Aβ degradation) |
Mice |
AAV5 |
[16] |
Intraparenchymal |
NGF (improving cholinergic activity) |
Rats |
AAV2 and AAV5 |
[17] |
Intraparenchymal |
NGF |
Mice |
CERE-110 (AAV2) |
[18] |
Intraparenchymal |
PHF1 (anti-phospho-TAU antibody) |
Mice |
AAVrh10 |
[19] |
Intraparenchymal |
CascFv59 (anti-Aβ antibody) |
Mice |
AAV2 |
[20] |
Intraparenchymal |
IL-10 (inhibition of proinflammatory cytokines) |
Mice |
AAV1 |
[21] |
Intramuscular and intravenous |
GFP |
Mice |
AAV9, exo-AAV9 (IM) and AAV8 (IV) |
[22] |
Intramuscular |
scFv (anti-Aβ antibody) |
Mice |
AAV1 |
[23] |
Intramuscular |
P75NTR (protective against Aβ) |
Mice |
AAV8 |
[24] |
Intracerebroventricular |
GFP |
Mice |
AAV1, AAV5, AAV8, AAV9, AAV2-BR1 and AAV2-PHP.eB |
[25] |
Huntington |
Intraparenchymal |
82Q (mutant Htt) |
Rats |
AAV2 |
[26] |
Intraparenchymal |
BDNF and GDNF |
Rats |
AAV2 |
[27] |
Intraparenchymal |
CRISPR/Cas9 (Htt) |
Mice |
AAV1 |
[28] |
Intraparenchymal |
SIRT3 (protective against oxidative and mitochondrial stress) |
Mice |
AAV-DJ |
[29] |
Intraparenchymal |
XBP1 (involved in the splicing events of Htt) |
Mice |
AAV2 |
[30] |
Intraparenchymal |
mRNA or siRNA (Htt) |
Mice |
AAV9 |
[31] |
Intraparenchymal |
iRNA (Htt) |
Mice |
AAV8 |
[32] |
Intraparenchymal |
Exon1-Q138 mHtt and Exon1-Q17 wildtype Htt |
Mice |
AAV9 |
[33] |
Intraparenchymal |
Human KRAB domain from KOX1 (ZNF10); ZNF10 represses mutant Htt expression |
Mice |
AAV9 |
[34] |
Intraparenchymal |
GFP |
Rats |
AAV1, AAV2 and AAV5 |
[35] |
Intraparenchymal |
GDNF (neurturin) |
Mice |
AAV8 |
[36] |
Intraparenchymal |
miHDS1 (Htt) |
Mice |
AAV1 |
[37] |
Intraparenchymal |
SREBP2 (to reverse synaptic defects in Huntington disease) |
Mice |
AAV5 |
[38] |
Intraparenchymal |
siRNA (Htt) |
Sheep |
AAV serotype not disclosed |
[39] |
Intravenous |
iRNA (Htt) |
Mice |
AAV1 |
[40] |
Intramuscular and intravenous |
shRNA (AAT) |
Mice |
AAV8 (IV) and AAV6 (IM) |
[41] |
Intrathecal |
miRNA based on endogenous mir155 backbone (Htt) |
Sheep |
AAV9 |
[42] |
Amyotrophic lateral sclerosis |
Intraparenchymal and intramuscular |
GFP |
Mice |
AAV1, AAV2, AAV5, AAV6, AAV7, AAV8 |
[43] |
Intravenous and intracisternal |
SOD1 |
Mice |
AAVrh10 |
[44] |
Intravenous |
IGF1 |
Mice |
AAV9 |
[45] |
Intravenous |
GDNF |
Rat |
AAV9 |
[46] |
Intracerebroventricular |
GFP |
Mice |
AAV9 |
[47] |
Intramuscular |
HGF in SOD1 model |
Mice |
AAV6 |
[48] |
Intramuscular |
hIGF1 in SOD1model |
Mice |
AAV9 |
[49] |
Intramuscular |
GDNF |
Mice |
AAV2 |
[50] |
Intramuscular |
GDNF |
Mice |
AAV2 |
[51] |
Intramuscular |
GFP |
Mice |
AAV1, AAV5, AAV8 and AAV9 |
[52] |
Intramuscular |
SOD1 |
Mice |
AAV6 |
[53] |
Intramuscular |
IGF1 and GDNF |
Mice |
AAV2 |
[54] |
Intramuscular |
IGF1 |
Mice |
AAV9 |
[55] |
Intrathecal |
GLT1 overexpression in SOD1 animal model |
Mice |
AAV8 |
[56] |
Intrathecal |
SOD1 |
Mice |
AAV9 |
[57] |
Intracisternal |
C9orf72 hexanucleotide repeat expansions (generates neuropathology) |
Mice |
AAV9 |
[58] |
Spinal muscular atrophy |
Intracerebroventricular and intraperitoneal |
GFP |
Mice |
AAV9 |
[59] |
Intracerebroventricular |
SMN1 (gene replacement strategy) |
Mice |
AAV9 |
[60] |
Intracerebroventricular (mice) and intracisternal (pigs and NHP) |
hSMN1 |
Mice, Pigs, and NHPs |
AAV9 |
[61] |
Intracerebroventricular and intravenous |
SMN1 |
Mice |
AAV9 |
[62] |
Intramuscular |
DOK7 (tuning down disease severity) |
Mice |
AAV9 |
[63] |
Intravenous |
SMN transgene |
Piglets and NHPs |
AAVhu68 |
[64] |
Intramuscular |
GFP |
Mice |
AAV9 |
[65] |
Intrathecal |
SMN2 (to rescue the SMA model) |
Mice |
AAV9 |
[66] |
Intracisternal |
miRNA |
Mice |
AAVrh10 |
[67] |
Vision disorders |
Subconjuntival |
GFP |
Mice |
AAV2, AAV6 and AAV8 |
[68] |
Intravenous |
CRISPR/Cas9 (retinitis pigmentosa) |
Mice |
AAV2, AAV6 and AAV8 |
[69] |
Subretinal |
TGF-β1 (retinitis pigmentosa) |
Mice |
AAV8 |
[70] |
GFP |
Mice and NHPs |
AAV7m8 and AAV8BP2 |
[71] |
GFP |
Mice |
AAV8, AAV9. AAV-PHP.B, AAV-PHP.eB |
[72] |
GFP |
Mice and pigs |
AAV8 |
[73] |
Retinal |
CRISPR/Cas9 (retinal editing) |
Mice |
AAV2 and AAV7 |
[74] |
Intravitreal |
CAD180 (endogenous inhibitor of angiogenesis) retinal neovascularization (RNV) |
Mice |
AAV2 |
[75] |
GFP |
NHPs |
AAV2 |
[76] |
GFP |
Mice and NHPs |
AAV2 |
[77] |
GFP |
Mice |
AAV2, AAV5, AAV8 and AAV9 |
[78] |
Hearing disorders |
Cochlear |
CRISPR/Cas9 (gene editing) |
Mice |
AAV2 |
[79] |
SYNE4 (to rescue in a deafness model) |
Mice |
AAV9-PHP.B |
[80] |
GFP |
Mice |
AAV2, AAV6, AAV8, AAV/Anc80L65 |
[81] |
GFP |
Mice and guinea pigs |
AAV2, AAV9 and Anc80L65 |
[82] |
Canalastomy (inner ear cells) |
GFP |
Mice |
AAV1, AAV2, AAV6.2, AAV8, AAV9, AAVrh.39, AAVrh.43 and Anc80L65 |
[83] |
CRISPR/Cas9 (GFP, Biodistribution) |
Mice |
AAV8 |
[84] |
Round window membrane |
XIAP against Cisplatin (chemotherapeutic agent) |
Mice |
AAV2 |
[85] |
GFP |
Mice and NHPs |
AAV9-PHP.B |
[86] |
Harmonin-a1 and harmonin-b1 (To rescue Usher syndrome type 1c) |
Mice |
AAV1 and AAV/Anc80L65 |
[87] |
GFP |
Mice |
AAV1 and exo-AAV1 |
[88] |
GFP |
Mice |
AAV2/DJ, AAV2/DJ8, AAV2-PHP.B |
[89] |
Utricle (inner and outer cells) |
GFP |
Mice |
AAV9-PHP-B, Anc80L65 and AAV2.7m8 |
[90] |